Eli M. Wallace
BridgeBio (United States)(US)
Publications by Year
Research Areas
Cancer, Hypoxia, and Metabolism, PI3K/AKT/mTOR signaling in cancer, Asymmetric Synthesis and Catalysis, Epigenetics and DNA Methylation, Renal cell carcinoma treatment
Most-Cited Works
- → Targeting renal cell carcinoma with a HIF-2 antagonist(2016)704 cited
- → On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models(2016)448 cited
- → Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma(2017)376 cited
- → A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma(2016)316 cited
- → 3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma(2019)202 cited
- → Synthetic Routes to Allenic Acids and Esters and Their Stereospecific Conversion to Butenolides(1997)187 cited
- → Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors(2012)184 cited
- → Structural Basis and Kinetic Pathway of RBM39 Recruitment to DCAF15 by a Sulfonamide Molecular Glue E7820(2019)174 cited
- → Total Synthesis of the Pseudopterane (.+-.)-Kallolide B(1995)147 cited
- → Suppression of HIF2 signalling attenuates the initiation of hypoxia-induced pulmonary hypertension(2019)115 cited